World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 28 March 2022
Main ID:  EUCTR2012-004631-22-BE
Date of registration: 11/12/2012
Prospective Registration: Yes
Primary sponsor: University Hospitals Leuven
Public title: TapERA: Tapering Etanercept in Reumatoid Artritis.
Scientific title: TapERA: Maintaining remission in RA while tapering Etanercept. - TapERA
Date of first enrolment: 15/01/2013
Target sample size: 120
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-004631-22
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: comperator is the standard dose of the same product (Enbrel 50 mg weekly versus every other week)
Number of treatment arms in the trial: 2
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes
Countries of recruitment
Belgium
Contacts
Name: Rene Westhovens   
Address:  herestraat 49 3000 Leuven Belgium
Telephone: 3216342541
Email: rene.westhovens@uzleuven.be
Affiliation:  University Hospitals Leuven
Name: Rene Westhovens   
Address:  herestraat 49 3000 Leuven Belgium
Telephone: 3216342541
Email: rene.westhovens@uzleuven.be
Affiliation:  University Hospitals Leuven
Key inclusion & exclusion criteria
Inclusion criteria:
Patients eligible for enrolment in the study must meet the following inclusion criteria:
- Established RA patients in remission according to DAS remission criteria for at least 6 months
- Treated with Etanercept 50mg weekly for at least one year
- DMARD treatment is allowed at a stable dose for at least 3m prior to baseline
- Stable oral corticosteroids treatment is allowed at a daily dose equal to or less than 5 mg prednisone equivalent for at least 1 month prior to randomisation
- Able and willing to give written informed consent and to participate in the study

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 90
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30

Exclusion criteria:
Patients will be excluded from participating in the study if they meet any of the following exclusion criteria:
- Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions, chronic or latent infectious diseases or immune deficiency, addiction to analgesics and all diseases which in the opinion of the investigator places the patient at an unacceptable risk for continuing therapy and participation in the study
- Pregnancy, breastfeeding or no use of a reliable method of contraception
- Alcohol or drug abuse



Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
reumatoid arthritis
MedDRA version: 14.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Intervention(s)

Trade Name: Enbrel
Product Name: Enbrel
Product Code: EMEA/H/C000262
Pharmaceutical Form: Solution for injection in pre-filled syringe

Primary Outcome(s)
Primary end point(s): The proportion of patients maintaining remission 6 months after decreasing the dose of Etanercept to 50mg every 2 weeks compared to the proportion of patients maintaining remission while continuing the established dose of 50mg weekly.
Timepoint(s) of evaluation of this end point: month 6
Main Objective: The aim of the current study is to explore the potential of a dose reduction of Etanercept on safety and persisting remission in RA patients.
Secondary Objective: Secondary, possible baseline predictors for the maintenance of remission will be explored and the percentage of patients regaining remission after a flare will be investigated.
Secondary Outcome(s)
Timepoint(s) of evaluation of this end point: Month 3, 6, 9 and 12
Secondary end point(s): - Exploring baseline predictors for the maintenance of remission (including ultrasound)
- Proportion of patients maintaining remission for 1 year
- Proportion of patients maintaining remission for 6 months and 1 year according to the Boolean definition
- Proportion of patients maintaining remission for 6 months and 1 year according to the SDAI definition
- Proportion of patients regaining remission status when retreated with their original dose of Etanercept
- Evaluating the usefulness the FLARE questionnaire
- Safety: number and type of (serious) adverse events.
Secondary ID(s)
TapERA2012
Source(s) of Monetary Support
department of rheumatology, University Hospitals Leuven
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 15/01/2013
Contact:
Results
Results available: Yes
Date Posted: 16/04/2021
Date Completed: 31/12/2015
URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004631-22/results
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey